Martine Vugt - Genmab AS Executive Officer

GMAB Stock  USD 23.33  0.37  1.61%   

Executive

Ms. Martine J. van Vugt, Ph.D. serves as Chief of Staff at Genmab AS. She has knowledge and experience in portfolio, project and alliance management, as well as business development operations related to corporate transactions and licensing.
Age 54
Address Carl Jacobsens Vej 30, Copenhagen, Denmark, 2500
Phone45 70 20 27 28
Webhttps://www.genmab.com

Genmab AS Management Efficiency

The company has return on total asset (ROA) of 0.1091 % which means that it generated a profit of $0.1091 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2297 %, meaning that it created $0.2297 on every $100 dollars invested by stockholders. Genmab AS's management efficiency ratios could be used to measure how well Genmab AS manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to 0.27. The current year's Return On Capital Employed is expected to grow to 0.17. At present, Genmab AS's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 18.9 B, whereas Other Current Assets are forecasted to decline to about 110.3 M.
Genmab AS currently holds 1.03 B in liabilities with Debt to Equity (D/E) ratio of 0.03, which may suggest the company is not taking enough advantage from borrowing. Genmab AS has a current ratio of 12.85, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Genmab AS's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

EXECUTIVE Age

James JDLegend Biotech Corp
N/A
Harp MBAVaxcyte
51
Camille MDAmylyx Pharmaceuticals
72
Prof MDDay One Biopharmaceuticals
55
Melita JungTerns Pharmaceuticals
48
Sam IkiVaxcyte
N/A
YulyMae DiNapoliCytokinetics
N/A
Jeffrey EiseleApellis Pharmaceuticals
62
John StubenrauchDay One Biopharmaceuticals
N/A
Adam TownsendApellis Pharmaceuticals
47
Adam JDDay One Biopharmaceuticals
58
John JDEdgewise Therapeutics
61
Shu WuLegend Biotech Corp
N/A
Alan KickLegend Biotech Corp
N/A
Kathryn HavilandBlueprint Medicines Corp
48
Tim RobertsLegend Biotech Corp
N/A
Liz GosenLegend Biotech Corp
N/A
Surabhi VermaLegend Biotech Corp
N/A
Debra DursoBumpusBlueprint Medicines Corp
55
Ariel HurleyBlueprint Medicines Corp
51
Steven GavelLegend Biotech Corp
N/A
Genmab AS develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. Genmab AS was founded in 1999 and is headquartered in Copenhagen, Denmark. Genmab AS is traded on NASDAQ Exchange in the United States. Genmab AS (GMAB) is traded on NASDAQ Exchange in USA. It is located in Carl Jacobsens Vej 30, Copenhagen, Denmark, 2500 and employs 2,682 people. Genmab AS is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Genmab AS Leadership Team

Elected by the shareholders, the Genmab AS's board of directors comprises two types of representatives: Genmab AS inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Genmab. The board's role is to monitor Genmab AS's management team and ensure that shareholders' interests are well served. Genmab AS's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Genmab AS's outside directors are responsible for providing unbiased perspectives on the board's policies.
Takahiro Hamatani, Senior Director
Birgitte MSc, Executive Officer
Marisol Peron, Senior Affairs
Christopher Cozic, Executive Officer
Tahamtan Ahmadi, Senior Vice President Oncology and Translational Medicine
Anthony CPA, Executive CFO
Anthony Mancini, Executive COO
Judith MD, Executive Officer
Anthony Pagano, Senior Vice President Global Finance and Corporate Development
Martine Vugt, Executive Officer
Andrew Carlsen, Senior Director, Investor Relations
Peter Ros, Sr Accounting
Martin Schultz, Senior Director
Rayne Waller, Executive Officer
Jan Winkel, President CoFounder
Mijke Zachariasse, Director Director
Rima Nassar, Head VP
Tahamtan MD, Chief VP

Genmab Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Genmab AS a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Genmab AS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Genmab AS's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Genmab As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Genmab As Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genmab AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
For information on how to trade Genmab Stock refer to our How to Trade Genmab Stock guide.
You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Genmab AS. If investors know Genmab will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Genmab AS listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
4.634
Earnings Share
1.71
Revenue Per Share
33.5366
Quarterly Revenue Growth
0.353
Return On Assets
0.1091
The market value of Genmab AS is measured differently than its book value, which is the value of Genmab that is recorded on the company's balance sheet. Investors also form their own opinion of Genmab AS's value that differs from its market value or its book value, called intrinsic value, which is Genmab AS's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Genmab AS's market value can be influenced by many factors that don't directly affect Genmab AS's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Genmab AS's value and its price as these two are different measures arrived at by different means. Investors typically determine if Genmab AS is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Genmab AS's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.